A genetic test could predict the odds of obesity, allowing for early interventions
Certain genetic variants can affect how a person's body stores fat or make them more prone to overeating. Genetic variation can also predict how well a person will respond to different weight loss drugs.
In a study published Monday in the journal Nature Medicine, more than 600 researchers from around the world worked together to compile genetic data from more than 5 million people — the largest and most diverse genetic dataset to date. They also used genetic data from 23andMe.
From the dataset, the researchers were able to create what's known as a polygenic risk score, which takes into account which genetic variants a person has that have been linked to a higher BMI in adulthood.
The score, the researchers said, could be used to predict a person's risk of obesity as an adult — before they even turn 5.
'Childhood is the best time to intervene,' said study co-author Ruth Loos, a professor at the University of Copenhagen's Novo Nordisk Foundation Center for Basic Metabolic Research. (Research conducted at the center is not influenced by drugmaker Novo Nordisk, though some of the study authors had ties to pharmaceutical companies that make weight loss drugs.)
The findings come as obesity is rising around the world. Rates of obesity in adults have more than doubled globally since 1990, and adolescent rates have quadrupled, according to the World Health Organization. About 16% of adults worldwide have obesity and the situation is worse in the United States, where more than 40% of adults have obesity, Centers for Disease Control and Prevention statistics show.
Twice as effective
The new test is not the first that predicts a person's risk of obesity, but Loos and her team showed it was about twice as effective as the method doctors currently use to assess their patients. That polygenetic score can account for about 8.5% of a person's risk for having a high BMI as an adult. The new score increased that to about 17.6%, at least in people with European ancestry.
'That's a pretty powerful risk indicator for obesity, but it still leaves open a lot that is unknown,' said Dr. Roy Kim, a pediatric endocrinologist at Cleveland Clinic Children's who was not involved with the research.
Based on this score, more than 80% of a person's risk for obesity can be explained by other factors, such as where they live, what kinds of foods they have access to, and how much they exercise.
The test was not nearly as effective in predicting obesity risk in non-Europeans. It explained about 16% of the risk for having a high BMI in East Asian Americans, but just 2.2% in rural Ugandans.
About 70% of people whose data was included in the study were of predominantly European ancestry. About 14% were Hispanic and typically had a mix of ancestries. About 8% were of predominantly East Asian descent and just under 5% were of predominantly African ancestry. These samples were predominantly from African American people, who largely had mixed ancestry. Just 1.5% were of predominantly South Asian ancestry.
Loos said the new score is a big step forward, but that it's still a prototype. The next step is to collect more — and more diverse — data on people with African ancestry in particular to improve how well the score works for everyone, not just white people.
She said the score could offer one indicator — what high blood pressure is to heart disease, for example — that could help predict a person's risk of developing obesity.
'Obesity is not only about genetics, so genetics alone can never accurately predict obesity,' Loos said. 'For the general obesity that we see all over the world, we need other factors such as lifestyle that need to be part of the predictions.' Genetics play a bigger role in severe obesity, meaning a BMI of more than 40, she added.
Still, identifying a person's genetic risk early on in childhood and intervening early with lifestyle coaching could make a big difference, she said. Research has shown that about 55% of children with obesity go on to have obesity in adolescence, and that about 80% of those individuals will have obesity in adulthood.
'Behavioral things are really important,' Kim said. 'Their environment, their access to healthy food, exercise opportunities, even their knowledge about healthy foods all affect a person's obesity risk.'
How important are genetics, really?
Although studies in identical twins have found that genetics can account for as much as 80% of the reason a person has obesity, lifestyle factors still play a huge role, Kim said.
'Even with the same genetic makeup, people can have different body types,' he said. 'From a very young age in my practice, we educate patients about the importance of eating protein-rich foods, a lot of fruits and vegetables and not too many refined carbs.'
Dr. Juliana Simonetti, co-director of the Comprehensive Weight Management Program at the University of Utah, has been using genetic testing in her adult patients for about five years. She said understanding a person's genes can help doctors better treat weight gain.
'Obesity is not homogeneous. We have different kinds and different presentations,' said Simonetti, who wasn't involved with the new study.
Simonetti uses a person's genes to determine if a patient struggles with satiety, or feeling full.
'They eat but do not feel full,' Simonetti said, adding that this is a disorder caused by genetic mutations affecting certain pathways in the body. People who have these mutations 'tend to have higher weight,' she said.
But such mutations do not tell the whole genetic story of obesity, Simonetti said. The genes that a person inherits from either parent, even if they are not mutations, also determine how a person's body stores weight or uses energy. Both can play a big role in obesity risk.
Genetic testing is also starting to be able to determine how well certain weight loss drugs will work for a person, Simonetti said, but she added this is just the beginning.
'We are talking about three out of 80 mutations that we can treat,' she said. 'We are getting better, and the more data we have, I'm hopeful that we are going to do a better job in being more precise in understanding treatment responses.'
This article was originally published on NBCNews.com
Solve the daily Crossword
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business of Fashion
27 minutes ago
- Business of Fashion
Ozempic Maker Novo Nordisk's Market Value Drops $93 Billion
Novo Nordisk named its head of international operations as chief executive officer after slumping weight-loss drug sales led to a profit warning that wiped $93 billion off its market value. The Danish drugmaker promoted Maziar Mike Doustdar, who has spent more than three decades with the company, to the top spot. The surprise choice disappointed investors who were hoping for a high-profile outsider to lead a fresh challenge to Eli Lilly & Co., which has been pulling ahead of Novo in the obesity market. The appointment came shortly after Novo slashed its financial forecast, predicting this year's sales will grow 8 to 14 percent, while operating profit expands 10 to 16 percent, based on constant exchange rates. That compares with its previous growth forecasts of as much as 21 and 24 percent, respectively. Shares of Novo plunged as much as 30 percent in Copenhagen, the biggest intraday drop on record. ADVERTISEMENT Doustdar said he plans to 'increase the sense of urgency and execute differently,' and his top priorities will be advancing Novo's drug pipeline, innovation and investing to deliver growth. The new CEO, who takes over on Aug. 7, also said on a call with journalists that he's planning to review the company's cost base, without citing specific targets for cuts. That indicates Novo is preparing for a period of slower growth after the initial surge of demand for its blockbuster obesity drug, Wegovy, that briefly made the company Europe's biggest by market value. 'Analysts will start to question both near-term and longer-term obesity expectations that have ballooned out of control,' said Jared Holz, a health-care strategist at Mizuho Securities USA LLC. Holz and other analysts questioned whether an insider will be able to restore investor confidence. Given the company's recent struggles, 'we are surprised by the choice of an internal candidate,' said Benjamin Jackson, an analyst at Jefferies LLC. Novo announced the ouster of former CEO Lars Fruergaard Jorgensen in May, seeking a reset following a string of setbacks. Though Doustdar, 54, is an insider at Novo, he brings a more international background than some of the company's previous leaders. He's Iranian-born, with Austrian citizenship. Novo's past CEOs have all been Danish and were intertwined with the company prior to taking over. Two were sons-in-law of previous company leaders. After enjoying an early advantage as a first mover in the obesity drug market, Novo is struggling with competition as Lilly's Zepbound wins market share over Wegovy. Lilly also appears better positioned to dominate for years to come. It has an easy-to-take weight-loss pill that will come to market as soon as early 2026 and it's studying a shot that's shown signs of being as effective as bariatric weight-loss surgery. Novo's own next-generation candidate, CagriSema, has fallen short of both the company's and analysts' hopes in clinical trials. ADVERTISEMENT The company is also facing competition from compounding pharmacies that are allowed to make copies of drugs when they are in short supply. Novo estimates about 1 million patients in the US are using compounders in the US market, Chief Financial Officer Karsten Munk Knudsen said on a call. Novo said it will fight compounding in the courts and invest in its own direct-to-patient marketing efforts. Novo has said a new contract with CVS Health Corp. for Wegovy would drive volume from July 1. The slashed forecast reflects competition for both Wegovy and its sister drug Ozempic for diabetes, the company said. The drugmaker also cited slower than expected market growth for weight-loss drugs. Novo's sales climbed 18 percent in constant currencies in the second quarter, the company said, with operating profit rising 40 percent. The company will publish complete second-quarter results on Aug. 6. The foundation that controls the company pushed for Jorgensen to go and instated his predecessor, Lars Rebien Sorensen, as an observer on Novo's supervisory board. Sorensen is set to return as a full board member next year. By Naomi Kresge, with assistance from Christian Wienberg, Lisa Pham, Thomas Hall and Marthe Fourcade Learn more: Zepbound Beats Wegovy in First Head-to-Head Trial Eli Lilly's GLP-1 drug Zepbound helped nearly 25 percent more participants lose weight than Novo Nordisk's Wegovy, according to the trial results.


New York Times
2 hours ago
- New York Times
Ozempic Maker's Stock Plunges 20% After Profit Warning
Shares of Novo Nordisk, the Danish drugmaker behind the popular diabetes and weight-loss drugs Ozempic and Wegovy, plummeted more than 20 percent on Tuesday after it said its sales this year would grow much less than previously expected. The drugmaker, which cited increased competition in the United States as a reason for its slower growth, said its sales would increase 8 to 14 percent this year, while operating profit growth is expected to be between 10 and 16 percent. At one point, the company had expected sales growth of 16 to 24 percent for 2025. The share price dropped to its lowest level in more than three years. The company also announced on Tuesday its new chief executive, Maziar Mike Doustdar, who is the current executive vice president for international operations. He will take over on Aug. 7. 'I don't like it,' Mr. Doustdar said of the company's share price drop on a call with reporters. 'I don't like it as an employee. I don't like it as a C.E.O.-elect and I certainly don't like it as a shareholder myself.' The announcement 'reinforces even more the urgency to act on the mandate I've been given,' he said. Novo Nordisk has experienced a sharp reversal in fortunes over the past year. It lost its title as Europe's most valuable company, first to the luxury empire LVMH and then to SAP, a German software company. In May, the board pushed out the company's chief executive, Lars Fruergaard Jorgensen, amid the steep decline in its stock price and shareholders' concerns that Novo Nordisk would lose its place as a front-runner in a highly competitive market. On top of this, some disappointing clinical trial results and investors' losing faith in the lofty expectations of the weight-loss drug industry have hit Novo Nordisk especially hard. The company has said most of its issues are in the United States, where it generates more than half of its sales. There, the company is facing stiff competition from other obesity medications, known as GLP-1 drugs, particularly the Eli Lilly drugs Mounjaro and Zepbound, as well as cheaper copycat versions. This year, the Food and Drug Administration banned the sale of the cheaper products made from a process of mixing drug ingredients called compounding. Mr. Jorgensen said the company's previous guidance had assumed that Novo Nordisk would be able to regain some of its lost market share after the ban on compounding weight-loss drugs. But that has not happened yet, he said, and there are more than one million patients using compounded GLP-1 drugs. Novo Nordisk said on Tuesday that sales in the first six months of the year had increased 18 percent and operating profit had risen 29 percent, but that growth would slow in the second half.


CBS News
2 hours ago
- CBS News
Novo Nordisk shares fall 20% after company names new CEO and lowers its financial outlook
Novo Nordisk shares plunged over 20% on Tuesday after the company named a new CEO and lowered its profit expectations, citing weaker sales of its popular weight-loss drug Wegovy due to competition from copycat drugs. In a statement on Tuesday, Novo Nordisk said it expects its sales for 2025 to grow 8%-14%, down from projections of 13%-21% in May. It also lowered its expectations for operating profit growth to 10%-16%, down from 16%-24% in May. The updated outlook "reflects the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition," the company said. Glucagon-like peptide-1 agonists (GLP-1s), a class of drugs used to manage diabetes, have upended the weight-loss industry. The Danish pharmaceutical company also announced on Tuesday the appointment of Maziar Mike Doustdar as president and CEO. Doustdar, who has worked at Novo Nordisk for over 30 years, will take the helm starting on Aug. 7. Doustdar will succeed Lars Fruergaard Jorgensen, who announced his departure as CEO of Novo Nordisk in May, following a steep decline in the company's share price, which has dropped nearly 37% since the start of this year. Reached for comment, a Novo Nordisk spokesperson said they did not have anything additional to share before the company's earnings call, which is scheduled for Wednesday, Aug. 6. While global sales of Wegovy are growing, sales of the weight-loss drug are expected to weaken in certain markets due to increased competition from compounded versions of the drug. Compounded weight-loss drugs have the same active ingredients as Wegovy and other popular brands such as Ozempic, and are used as substitutes when the name-brand drugs aren't available. However, the Food and Drug Administration (FDA) in April said there is no longer a shortage of GLP-1s and ordered compounding pharmacies to stop selling their copycat versions of the popular weight-loss drugs. Despite efforts to stymie them, however, compounded versions of the drugs continue to penetrate the market, giving consumers a cheaper option to name-brands like Wegovy, which can cost more than $1000 per package for those without insurance. In June, Novo Nordisk ended its partnership with Hims & Hers Health over claims that the online drug retailer was selling fake versions of Wegovy, a move Novo Nordisk said "put patient safety at risk." CBS News medical contributor Dr. Céline Gounder told CBS News last year that there is not a lot of oversight over the compounded drug market, and that there is a wide range when it comes to the quality and risk associated with each drug. Novo Nordisk said it is pursuing multiple avenues to "protect patients from knockoff 'semaglutide' drugs" including litigation. Semaglutide is the active ingredient found in Wegovy and Ozempic. "Novo Nordisk is deeply concerned that, without aggressive intervention by federal and state regulators and law enforcement, patients will continue to be exposed to the significant risks posed by knockoff 'semaglutide' drugs made with illicit or inauthentic foreign active pharmaceutical ingredients," the company said in its Associated Press contributed to this report.